Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-γ, or combination IL-2+IFN-γ

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 2, 1998, Pages 95-103

  Kircheis, R ^a   Kupcu Z ^a   Wallner, G ^a   Wagner, E ^a  

^a Bender and Co GmbH   (Austria)

Author keywords

Interferon ; Interleukin 2; Melanoma; Vaccination

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE TRANSFER; GENETIC ENGINEERING; IMMUNE RESPONSE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0031816638     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Fearon ER, Pardoll DM, Itaya T et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60: 397-403.
2. Gansbacher B, Zier K, Daniels B et al, Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med (1990) 172: 1217-24.
3. Colombo MF, Ferrari G, Stoppacciaro A et al, Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 173. 889-97.
4. Blankenstein T, Qin Z, Überla K et al, Tumor suppression after tumor cell-targeted tumor necrosis factor-α gene transfer. J Exp Med (1991) 173: 1047-52.
5. Tepper RI, Coffman RL, Leder P, An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science (1992) 257: 548-51.
6. Hock H, Dorsch M, Kunzendorf U et al, Mechanism of rejection induced by tumor cell-targeted gene transfer of intcrleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA (1993) 90: 2774-8.
7. Gansbacher B, Bannerji R, Daniels B et al, Retroviral vectormediated γ-interferon gene transfer into tumor cells generates potent and long-lasting anutumor immunity. Cancer Res (1990) 50: 7820-5.
8. Zatloukal K, Schmidt W, Cotten M et al, Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. Gene (1993) 135: 199-207.
9. Zatloukal K, Schneeberger A, Berger M et al, Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine. J Immunol (1995) 154: 3406-19
10. Porgador A, Gansbacher B, Bannerji R et al, Antimetastatic vaccination of tumor-bearing mice with IL-2 gene-inserted tumor cells. Int J Cancer (1993) 53: 471-7.
11. Golumbek PT, Azhari EM, Jaffee LM et al, Controlled release, biodegradable cytokine deposits: a new approach in cancer vaccine design. Cancer Res (1993) 53 5841-4.
12. Pardoll DM, Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol (1995) 13: 399-415.
13. Jaffee EM, Thomas MC, Huang AYC et al, Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother (1996) 19: 176-83.
14. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
15. Abdel-Wahab Z, Dar M, Osanto S et al, Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther (1997) 4: 33-41.
16. Connor J, Bannerji R, Saito S et al, Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med (1993) 177: 1127-34.
17. Cortesina G, De Stefani A, Galeazzi E et al, Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with low but not with high dose of recombinat interleukin-2 injected perilymphatically. Br J Cancer (1994) 69: 572-6.
18. Schmidt W, Schweighoffer T, Herbst E et al, Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA (1995) 92: 4711-14.
19. Gray PW, Goeddel DV, Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci USA(1983) 80: 5841-6.
20. Cotten M, Baker A, Saltik M et al, Lipopolysaccharide is a frequent contaminant in plasmid preparations and can be toxic to primary cells in the presence of adenovirus. Gene Ther (1994) 1: 239-46.
21. Wagner E, Zatloukal K, Cotten M et al, Coupling of adenovirus to polylysine-DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA (1992) 89: 6099-103.
22. Karasuyama H, Melchers F, Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol (1988) 18: 97-104
23. Harms JS, Splitter GA, Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther (1995) 6: 1291-7.
24. Clary BM, Coveney EC, Philip R et al, Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther (1997) 4. 97-104.
25. Maass G, Schweighoffer T, Berger T et al, Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo. Int J Immunopharmacol (1995) 17: 65-73.
26. Ferrantini M, Giovarelli M, Modesti A et al, IFN-α1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. J Immunol (1994) 153: 4604-15.
27. Clary BM, Coveney EC, Blazer III DG et al, Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery (1996) 120: 174-81.
28. Schweighoffer T, Berger M, Buschle M et al, Adenovirus-enhanced receptor-mediated transferrinfection for generation of tumor vaccines. Cytokines Mol Ther (1996) 2: 185-92.